10:09 AM EDT, 07/15/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Tuesday that a new analysis of real-world data from the CAHtalog registry showed the need for congenital adrenal hyperplasia therapies to reduce androgen excess without high glucocorticoid doses.

The analysis demonstrated "considerable" variability in glucocorticoid treatment regimens and frequent changes across health states, most of which were marked by higher glucocorticoid doses and/or androstenedione levels, the company said.

Neurocrine said 95.2% of the patients entered a suboptimal health state, defined as receiving high glucocorticoid doses and/or having increased androstenedione levels at least once during the follow-up period, Neurocrine said.

Neurocrine Chief Medical Officer Sanjay Keswani said the analysis shows that the data showed how "dynamic and unpredictable" disease control can be. "Achieving disease control today, often with the use of high-dose glucocorticoids, offers no guarantee of maintaining disease control long term," he said.

Price: 136.00, Change: +0.87, Percent Change: +0.64